Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec... ( Reaffirms Adjusted Diluted EPS Guidan...)

HOME >> BIOLOGY >> TECHNOLOGY

Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008

Date:2/19/2009

Reaffirms Adjusted Diluted EPS Guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for 2010

PITTSBURGH, Feb. 19 /PRNewswire-FirstCall/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three and twelve months ended Dec. 31, 2008 and reaffirmed adjusted diluted EPS guidance of $0.90 to $1.10 for 2009 and $1.50 to $1.70 for 2010.

Financial Highlights

Adjusted diluted EPS of $0.26 and $0.80 for the three and twelve months ended Dec. 31, 2008, respectively, which excludes the impact of certain purchase accounting items as well as other non-cash and/or non-recurring items as detailed below;
Total revenues of $1.20 billion for the three months ended Dec. 31, 2008, an increase of $47.8 million over the same prior year period;
Total revenues of $5.14 billion for the twelve months ended Dec. 31, 2008, an increase of $2.47 billion over the twelve months ended Dec. 31, 2007;
On a GAAP basis, the company reported a loss per diluted share of $0.13 for the three months ended Dec. 31, 2008, and a loss per diluted share of $1.05 for the calendar year ended Dec. 31, 2008.

Mylan's Vice Chairman and CEO Robert J. Coury commented: "Never in Mylan's history has there been a more transformational year than 2008. We successfully combined three high-quality, complementary and industry-leading platforms into one efficient global organization. We integrated operations, cultivated a talented management team and installed global systems. We also significantly broadened our product portfolio, leveraged our commercial footprint and continued to streamline our cost structure. All of this was achieved while we met or exceeded our stated financial expectations."

Coury continued: "
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related biology technology :

1. Mylan Announces Pricing of Tender Offers for its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015
2. Mylan to Host Investor Day on October 3, 2007
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Mylan Announces Appointment of Steven G. Zylstra as Vice President of Global Corporate Communication and Public Relations
5. Mylan Announces Tentative FDA Approval for Lamotrigine Tablets
6. Mylan Announces Final FDA Approval for Balsalazide Disodium Capsules
7. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
8. Mylan Announces Final FDA Approval for Ropinirole Hydrochloride Tablets
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
11. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008

Post Your Comments:

Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec...( Reaffirms Adjusted Diluted EPS Guidan...)